Jin Wang

Jin Wang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Insect Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
HLHanhan Liu
Hanhan Liu
JWJin Wang
Jin Wang
SLSheng Li
Sheng Li

26 December 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CCChunyan Cheng
Chunyan Cheng
TWTao Wang
Tao Wang
ZSZhiqun Song
Zhiqun Song
LPLijun Peng
Lijun Peng
MGMengqing Gao
Mengqing Gao
JWJin Wang
Jin Wang
Diffuse large B‐cell lymphoma (DLBCL) is the most common form of non‐Hodgkin's lymphoma. R‐CHOP is currently the standard therapy for DLBCL, but the prognosis of refractory or recurrent patients remains poor. In this study, we synthesized a new water‐soluble antimalarial drug artemisinin derivative, SM1044. The treatment of DLBCL cell lines with SM1044 induces autophagy‐dependent apoptosis, which is directed by an accelerated degradation of the antiapoptosis protein Survivin, via its acetylation‐dependent interaction with the autophagy‐related protein LC3‐II. Additionally, SM1044 also stimulates the de novo synthesis of ceramide, which in turn activates the CaMKK2–AMPK–ULK1 axis, leading to the initiation of autophagy. Our findings not only elucidate the mechanism of autophagy‐dependent apoptosis in DLBCL cells, but also suggest that SM1044 is a promising therapeutic molecule for the treatment of DLBCL, along with R‐CHOP regimen.

20 October 2021 in Frontiers of Medicine
Verified
Journal Article
Closed access
PDF file
MXMengping Xi
Mengping Xi
SGShanshan Guo
Shanshan Guo
CBCaicike Bayin
Caicike Bayin
LPLijun Peng
Lijun Peng
FCFlorent Chuffart
Florent Chuffart
JWJin Wang
Jin Wang

31 August 2021 in Frontiers of Medicine
Verified
Journal Article
Closed access
PDF file
SWSisi Wang
Sisi Wang
LPLijun Peng
Lijun Peng
WXWenqian Xu
Wenqian Xu
YZYuebo Zhou
Yuebo Zhou
ZZZiyan Zhu
Ziyan Zhu
JMJian-Qing Mi
Jian-Qing Mi

15 February 2024 in Haematologica
Verified
Journal Article
Open access
PDF file
WXWenqian Xu
Wenqian Xu
FTFeng Tian
Feng Tian
XTXiaolu Tai
Xiaolu Tai
GSGaoxian Song
Gaoxian Song
YLYuanfang Liu
Yuanfang Liu
JMJian-Qing Mi
Jian-Qing Mi
ETV6::ACSL6 represents a rare genetic aberration in hematopoietic neoplasms and is often associated with severe eosinophilia, which confers an unfavorable prognosis requiring additional anti-inflammatory treatment. However, since the translocation is unlikely to produce a fusion protein, the mechanism of ETV6::ACSL6 action remains unclear. Here, we performed multi-omics analyses of primary leukemia cells and patient-derived xenografts from an acute lymphoblastic leukemia (ALL) patient with ETV6::ACSL6 translocation. We identified a super-enhancer located within the ETV6 gene locus, and revealed translocation and activation of the super-enhancer associated with the ETV6::ACSL6 fusion. The translocated super-enhancer exhibited intense interactions with genomic regions adjacent to and distal from the breakpoint at chromosomes 5 and 12, including genes coding inflammatory factors such as IL-3. This led to modulations in DNA methylation, histone modifications, and chromatin structures, triggering transcription of inflammatory factors leading to eosinophilia. Furthermore, the bromodomain and extraterminal domain (BET) inhibitor synergized with standard-of-care drugs for ALL, effectively reducing IL-3 expression and inhibiting ETV6::ACSL6 ALL growth in vitro and in vivo. Overall, our study revealed for the first time a cis-regulatory mechanism of super-enhancer translocation in ETV6::ACSL6ALL, leading to an ALL-accompanying clinical syndrome. These findings may stimulate novel treatment approaches for this challenging ALL subtype.

15 October 2017 in Stem Cells and Development
Verified
Journal Article
Open access
YWYan-Yu Wang
Yan-Yu Wang
WCWen-Lian Chen
Wen-Lian Chen
XWXiang-Qin Weng
Xiang-Qin Weng
YSYan Sheng
Yan Sheng
JWJing Wu
Jing Wu
JWJin Wang
Jin Wang
Recent reports state that C-type lectin-like molecule-1 (CLL-1) in acute myeloid leukemia (AML) is expressed primarily on myeloid cells, but there is still no investigation about its prognostic significance on leukemic blast compartment. Hence, this study aimed to evaluate the prognostic value of CLL-1 in 123 patients with de novo CD34+ Non-M3 AML. Multiparameter flow cytometry was used to assess the expression of CLL-1 on immature compartment in AML and control groups. We found that CLL-1 expression level on blast compartment was closely linked to clinical characteristics, treatment response, and survival outcome of patients. Decreased expression of CLL-1 was observed on immature compartment from AML patients as compared with controls (62.6% vs. 86.5%, P < 0.05). Logistic model exhibited that CLL-1low independently predicted low complete remission rate with an odds ratio of 4.57 (2.53–6.61, P < 0.05). Additionally, CLL-1 expression level at diagnosis was inversely correlated to the residual blast cells (residual leukemia cell) after induction chemotherapy (r = −0.423, P < 0.05). Furthermore, multivariate Cox regression model demonstrated that CLL-1low was still an independent adverse predictor (P < 0.05 for event-free survival, P < 0.05 for overall survival). Notably, CLL-1low was able to discriminate poor survival patients from intermediate- and favorable-risk groups. Taken together, CLL-1 is a novel prognostic predictor that could be exploited to supplement the current AML prognostic risk stratification system, and potentially optimize the clinical management of AML.